首页> 美国卫生研究院文献>The Journal of Pharmacology and Experimental Therapeutics >Blocking Sirtuin 1 and 2 Inhibits Renal Interstitial Fibroblast Activation and Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy
【2h】

Blocking Sirtuin 1 and 2 Inhibits Renal Interstitial Fibroblast Activation and Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy

机译:阻断Sirtuin 1和2在阻塞性肾病中抑制肾间质成纤维细胞活化并减轻肾间质纤维化。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Our recent studies revealed that blocking class I/II histone deacetylases (HDACs) inhibits renal interstitial fibroblast activation and proliferation and alleviates development of renal fibrosis. However, the effect of class III HDAC, particularly sirtuin 1 and 2 (SIRT1 and SIRT2), inhibition on renal fibrogenesis remains elusive. Here, we demonstrate that both SIRT1 and SIRT2 were expressed in cultured renal interstitial fibroblasts (NRK-49F). Exposure of NRK-49F to sirtinol, a selective inhibitor of SIRT1/2, or EX527 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide), an inhibitor for SIRT1, resulted in reduced expression of fibroblast activation markers (α-smooth muscle actin, fibronectin, and collagen I) as well as proliferation markers (proliferating cell nuclear antigen, cyclin D1, cyclin E) in dose- and time-dependent manners. Treatment with a SIRT2 inhibitor, AGK2 (2-cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide), also dose- and time-dependently inhibited renal fibroblast activation and, to a lesser extent, cell proliferation. Furthermore, silencing of either SIRT1 or SIRT2 by small interfering RNA exhibited similar inhibitory effects. In a mouse model of obstructive nephropathy, administration of sirtinol attenuated deposition of collagen fibrils as well as reduced expression of α-smooth muscle actin, collagen I, and fibronectin in the injured kidney. SIRT1/2 inhibition–mediated antifibrotic effects are associated with dephosphorylation of epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor-β (PDGFRβ), and signal transducer and activator of transcription 3. Thus, SIRT1/2 activity may contribute to renal fibroblast activation and proliferation as well as renal fibrogenesis through activation of at least EGFR and PDGFRβ signaling. Blocking SIRT1/2 activation may have therapeutic potential for the treatment of chronic kidney disease.
机译:我们最近的研究表明,阻断I / II类组蛋白脱乙酰基酶(HDAC)可抑制肾间质成纤维细胞的活化和增殖,并减轻肾纤维化的发展。但是,III类HDAC,特别是sirtuin 1和2(SIRT1和SIRT2)对肾纤维发生的抑制作用仍然难以捉摸。在这里,我们证明SIRT1和SIRT2都在培养的肾间质成纤维细胞(NRK-49F)中表达。将NRK-49F与SIRT1 / 2的选择性抑制剂sirtinol或SI527的抑制剂EX527(6-氯-2,3,4,9-四氢-1H-咔唑-1-羧酰胺)接触会降低成纤维细胞活化标志物(α-平滑肌肌动蛋白,纤连蛋白和胶原蛋白I)以及增殖标志物(增殖细胞核抗原,细胞周期蛋白D1,细胞周期蛋白E)的表达呈剂量和时间依赖性。用SIRT2抑制剂AGK2(2-氰基-3- [5-(2,5-二氯苯基)-2-呋喃基] -N-5-喹啉基-2-丙烯酰胺)治疗也可以剂量和时间依赖性抑制肾脏成纤维细胞活化,并在较小程度上促进细胞增殖。此外,通过小的干扰RNA沉默SIRT1或SIRT2表现出相似的抑制作用。在阻塞性肾病的小鼠模型中,给予西地替诺可减轻胶原蛋白原纤维的沉积,并减少受损肾脏中α-平滑肌肌动蛋白,胶原蛋白I和纤连蛋白的表达。 SIRT1 / 2抑制介导的抗纤维化作用与表皮生长因子受体(EGFR),血小板源性生长因子受体-β(PDGFRβ)以及信号转导子和转录激活子的去磷酸化有关。因此,SIRT1 / 2活性可能有助于至少通过激活EGFR和PDGFRβ信号传导来抑制肾成纤维细胞的活化和增殖以及肾纤维化。阻断SIRT1 / 2激活可能具有治疗慢性肾脏疾病的治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号